Schmidt-Brand succeeds Llewellyn-Davis at Wilex
This article was originally published in Scrip
Wilex CFO Peter Llewellyn-Davis will step down upon expiry on his contract to pursue new professional challenges. He will be succeeded by Dr Jan Schmidt-Brand, currently managing director of Wilex's Heidelberg Pharma GmbH subsidiary, effective 1 September 2012. Mr Llewellyn-Davis will act as an advisor to Wilex and will fully manage and complete the capital measure announced by the company on 3 August 2012.
You may also be interested in...
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.
Tapping into the ability of arenaviruses to deliver prolonged local immune activation, rapid regression of localized and metastatic cancers, and long-term disease control, Essen, Germany-based start-up Abalos Therapeutics has raised €12m to advance its lead candidates towards clinical testing.
Celgene agrees to pay $75m upfront for options to three Immatics TCR-T targets for solid tumors. Deal could be worth up to $1.59bn to the German biotech, which also retains option to co-develop and co-fund certain licensed products.